Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.

Described herein are compositions of collagen and micronized placental tissue components, methods for producing the same and methods for using the same for wound healing, repairing damaged tendons, cosmetic applications and covering biocompatible materials and/or devices.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease. In many cases, fibrinogen may be absent, which may reduce scarring.

Hemostatic compositions including a combination of more than one hemostatic agent, and devices coated or impregnated therewith, have been developed. Nanotechnology yields hemostatic agents with large surface areas thereof, thereby increasing the hemostatic properties of the device to which they are applied. By combining more than one hemostatic agent and utilizing one or more different nanotechnology approaches to enhance the surface areas thereof, the capability of the dressing to stop bleeding is improved via more than one mechanism, and thus provides better hemostasis.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

An improvement to the effectiveness or take of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition.

Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

Methods, compositions, and treatment protocols for treating ischemic wounds and inflammatory conditions in a patient. The treatment protocols comprise or consist of using a modified collagen gel (MCG) to promote healing of ischemic wounds and reduce inflammation at the wound site and in other inflammatory conditions. The modified collagen gel comprises generally a dispersion of collagens in an aqueous matrix comprising water and glycerine, where the amount of Type I collagen is greater than the amount of Type II and Type III collagens in the gel.

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.